Galectin Therapeutics to Present at 4th Global NASH Congress
April 27 2021 - 9:27AM
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of
therapeutics that target galectin proteins, today announced that
Pol F. Boudes, M.D., Chief Medical Officer, will present the
belapectin program at the 4th Global NASH Congress taking place
virtually on April 28 and 29, 2021.
On Thursday, April
29th, Dr. Boudes will review Galectin Therapeutics’ scientific and
clinical activities in NASH cirrhosis, followed by a Q&A
session. Only registered attendees are able to view the
presentation. Additional details can be found below:
Title: An
innovative clinical development program: belapectin for NASH
cirrhosisDate: Thursday, April 29,
2021Time: 11:45 am, British Summer Time, 6:45 am
Eastern
Belapectin, a
galectin-3 (Gal-3) inhibitor, is in development for the prevention
of esophageal varices in patients with NASH cirrhosis. Patients
with cirrhosis are in dire need of new therapeutic options as,
currently, their only hope is a liver transplant. Gal-3, a glycan
binding protein, orchestrates liver inflammation and fibrosis in
NASH cirrhosis. Belapectin is a large polysaccharide that binds
Gal-3 and is primarily captured by macrophages, thus inhibiting
Gal-3 at its main site of production.
A phase 2 study
indicated that belapectin appeared safe, was well tolerated, and
could reduce portal hypertension and prevent esophageal varices in
patients who have not yet developed them. Galectin is conducting a
seamless, adaptive, double-blind, randomized, placebo controlled
phase 2b/3 global study in patients with portal hypertension due to
NASH cirrhosis who have not yet developed varices. The primary
outcome is the development of esophageal varices at 18 months.
The annual Global NASH
Congress, usually held in London, will be taking place virtually on
April 28 and 29, 2021. The conference aims to facilitate
collaboration among the multiple communities working on liver
health, especially those researching non-alcoholic steatohepatitis
(NASH) and fatty liver disease (NAFLD). To learn more, visit:
http://www.global-engage.com/event/nash/.
About Galectin
Therapeutics
Galectin Therapeutics
is dedicated to developing novel therapies to improve the lives of
patients with chronic liver disease and cancer. Galectin’s lead
drug belapectin (formerly known as GR-MD-02) is a
carbohydrate-based drug that inhibits the galectin-3 protein which
is directly involved in multiple inflammatory, fibrotic, and
malignant diseases, for which it has Fast Track designation by the
U.S. Food and Drug Administration. The lead development program is
in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most
advanced form of NASH-related fibrosis. This is the most common
liver disease and one of the largest drug development opportunities
available today. Additional development programs are in treatment
of combination immunotherapy for advanced melanoma and other
malignancies. Galectin seeks to leverage extensive scientific and
development expertise as well as established relationships with
external sources to achieve cost-effective and efficient
development. Additional information is available at
www.galectintherapeutics.com.
Forward
Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
relate to future events or future financial performance, and use
words such as “may,” “estimate,” “could,” “expect” and others. They
are based on management’s current expectations and are subject to
factors and uncertainties that could cause actual results to differ
materially from those described in the statements. These statements
include those regarding the hope that Galectin’s development
program for belapectin will lead to the first therapy for the
treatment of fatty liver disease with cirrhosis and those regarding
the hope that our lead compounds will be successful in cancer
immunotherapy and in other therapeutic indications. Factors that
could cause actual performance to differ materially from those
discussed in the forward-looking statements include, among others,
that trial endpoints required by the FDA may not be achieved;
Galectin may not be successful in developing effective treatments
and/or obtaining the requisite approvals for the use of belapectin
or any of its other drugs in development; the Company may not be
successful in scaling up manufacturing and meeting requirements
related to chemistry, manufacturing and control matters; the
Company’s current NAVIGATE clinical trial and any future clinical
studies as modified to meet the requirements of the FDA may not
produce positive results in a timely fashion, if at all, and could
require larger and longer trials, which would be time consuming and
costly; plans regarding development, approval and marketing of any
of Galectin’s drugs are subject to change at any time based on the
changing needs of the Company as determined by management and
regulatory agencies; regardless of the results of any of its
development programs, Galectin may be unsuccessful in developing
partnerships with other companies or raising additional capital
that would allow it to further develop and/or fund any studies or
trials. Galectin has incurred operating losses since inception, and
its ability to successfully develop and market drugs may be
impacted by its ability to manage costs and finance continuing
operations. Global factors such as COVID-19 may limit access to
NASH patient populations around the globe and slow trial enrollment
and prolong the duration of the trial and significantly impact
associated costs as well as impact other trial related activities
including, amongst others, manufacturing and regulatory reviews.
For a discussion of additional factors impacting Galectin’s
business, see the Company’s Annual Report on Form 10-K for the year
ended December 31, 2020, and subsequent filings with the SEC. You
should not place undue reliance on forward-looking statements.
Although subsequent events may cause its views to change,
management disclaims any obligation to update forward-looking
statements.
Company
Contact:Jack Callicutt, Chief Financial Officer(678)
620-3186ir@galectintherapeutics.com
Galectin Therapeutics and
its associated logo is a registered trademark of Galectin
Therapeutics Inc. Belapectin is the USAN assigned name for Galectin
Therapeutics’ galectin-3 inhibitor GR-MD-02.
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Sep 2023 to Sep 2024